No Data
Eton Gains as Rare Disease Therapy Undergoes FDA Review
Stocks to Watch: Eton Pharmaceuticals, Match Group, Trump Media & Technology Group
By Connor Hart Eton Pharmaceuticals on Monday said that the Food and Drug Administration accepted its new drug application for ET-400, a formulation of hydrocortisone oral solution. Shares of the
Express News | Eton Pharmaceuticals Shares Are Trading Higher After the Company Announced FDA Acceptance of the New Drug Application for ET-400
Express News | Eton Pharmaceuticals Inc - Et-400 Patent Protection Through 2043
Express News | Eton Pharmaceuticals Inc: Prescription Drug User Fee Act (Pdufa) Target Action Date Is February 28, 2025
Express News | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for Et-400 (Hydrocortisone Oral Solution)
151364853 : It will be up premarket